Recipharm Pharmaservices Private Limited - Due diligence report

A 360° intelligence report on Recipharm: trust score, financial health, credit view, compliance, directors, growth and distress signals - ge…

2015-12-30 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
RP Recipharm Pharmaservices Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Recipharm — 360° Intelligence Report

Generated from MCA filings & public records
80/100
Trust Score
Low Risk

Recipharm is assessed as Low Risk with a Trust Score of 80/100. Recipharm is an active private limited indian non-government company incorporated in 2015, operating in the Chemicals sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Recipharm Pharmaservices Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
56/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 56/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • 1 auditor resignation(s) filed - latest: B S D & Co on 2017-05-05.
  • Delayed payments to MSME suppliers disclosed (4 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 75/100
NameDIN / PANDesignationAppointedTenureDIN status
INA QUINN 01234567 Director 01/04/2018 6 yrs Approved
Sourish Mittra 01234567 Director 01/04/2018 6 yrs Approved
Anita Ramgopal Borulkar 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 4 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Recipharm Lifesciences India Private Limited
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Recipharm Lifesciences India Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Net margin improved to 61%.
Operating for 10+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (56/100).
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 50.67 Lakh.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment85/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view87/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
03 Dec 2025
Director appointed
Anita Ramgopal Borulkar (Additional Director)
22 Sep 2025
Director appointed
Sourish Mittra (Additional Director)
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Share transfer (FY 2024)
2000000.00000000 shares to Recipharm Holding India Private Li
Latest balance sheet
Filed with ROC
16 Jan 2024
Director ceased
Srinivas Rao Davuluri
31 Oct 2023
Director ceased
KARAN BAGARIA
Director ceased
ANURAG BAGARIA
29 Sep 2023
Director ceased
INA QUINN
05 Jan 2023
Director appointed
INA QUINN (Director)
28 Nov 2022
Director ceased
SURESH NAGAPPA GANACHARI
11 Nov 2022
Director ceased
JEAN FRANCOIS HILAIRE
15 Mar 2022
Director ceased
MARK QUICK ROYSTON
31 Dec 2021
Director ceased
LISA MARIA KRISTINA LUNDBERG
26 Mar 2021
Director ceased
THOMAS BENGT ELDERED
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Aristo Laboratories Private Limited U24110MH1980PTC266205 Mumbai, Maharashtra, India
Lords Mark U21001MH1998PLC115601 Mumbai, Maharashtra, India
Milan Laboratories (India) U24230MH2003PTC139736 Thane, Maharashtra, India
Cropnosys India U24129KA2006PTC158618 Bangalore, Karnataka, India
Toyotsu Rare Earths India Private Limited U51420AP2009FTC082696 Anakapalle, Andhra Pradesh, India
Unison Pharmaceuticals Private Limited U24232GJ2001PTC079092 Ahmedabad, Gujarat, India
Keltech Energies L30007KA1977PLC031660 Bangalore, Karnataka, India
Lasons India U27104MH1979PTC021757 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Recipharm before audits and certifications: compliance score 56/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Recipharm: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Recipharm - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Recipharm pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Recipharm - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Recipharm an active company?

Recipharm has MCA status “Active” with a compliance score of 56/100 (Moderate).

Is Recipharm financially healthy?

Recipharm has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Recipharm?

Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Recipharm?

The ultimate holding entity is Recipharm Lifesciences India Private Limited. 3 active director(s) are on record.

Does Recipharm have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Recipharm up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 56/100 (Moderate).

Is it risky to lend to Recipharm?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.